Publications by authors named "Ye Chan Yoon"
Article Synopsis
- - The study compares the cardiac safety and effectiveness of a trastuzumab biosimilar (SB3) to the original trastuzumab (TRZ) for treating ERBB2-positive breast cancer over a follow-up period of up to 6 years.
- - Conducted from April 2016 to January 2021, the trial included 538 female patients, with both treatment groups receiving neoadjuvant chemotherapy followed by adjuvant therapy, and monitored for heart-related side effects.
- - Primary outcomes measured were cardiac issues like heart failure and reduced left ventricular function, with secondary outcomes focusing on event-free and overall survival rates between the two treatment options.
SB8 is a biosimilar of bevacizumab based on its similarity demonstrated by physicochemical, functional, non-clinical and clinical studies. Supported by the concept of extrapolation, SB8 was authorized and is used in a similar manner across all types of tumors as reference bevacizumab. Furthermore, SB8 offers convenience with prolonged stability compared with reference bevacizumab in diluted form.
View Article and Find Full Text PDFBackground: We assessed long-term cardiac safety and efficacy in patients with human epidermal growth factor receptor 2-positive early breast cancer treated with a trastuzumab biosimilar (SB3) or its reference product, trastuzumab (TRZ), in a phase 3 study.
Methods: Patients who completed the phase 3 study could be enrolled in this extension study. The outcomes included the incidence of symptomatic congestive heart failure (CHF), asymptomatic significant left ventricular ejection fraction (LVEF) decrease, incidence of other cardiac events, event-free survival (EFS), and overall survival.